Healthcare Professional Portal
Healthcare Professional Portal
The third in our 2026 Beyond sleepless nights: managing chronic insomnia in adults webinar series, in collaboration with MIMS Learning.
Dr Cameron Livingston, GP with Special Interest in Sleep Medicine, explores the clinical overlap between sleep apnoea and chronic insomnia, and the cumulative burden these conditions place on patients. Dr Livingston will explore diagnosis, treatment pathways and practical strategies for managing both disorders with a personalised approach to care. He also looks at the role of QUVIVIQ®▼ (daridorexant) in the management of chronic insomnia in these patients.
MIMS WEBINAR SERIES
Join us for this MIMS Learning webinar series focusing on chronic insomnia in adults. Over five webinars throughout 2026, our expert speakers will explore the impact of chronic insomnia in diverse patient populations and discuss diagnostic approaches.
They will also highlight recommendations for chronic insomnia management in clinical practice, including pharmacological interventions such as QUVIVIQ (daridorexant), as well as lifestyle and psychological approaches.
Click the button below to find out more and register via MIMS Learning:
One of our product specialists would be happy to answer your questions.
QUVIVIQ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1
References
1 – QUVIVIQ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
1 – QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
2 – Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708.
3 – NICE Clinical Knowledge Summary (CKS) Insomnia: Scenario: Managing long-term insomnia (more than 3 months duration). Available at: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/. Updated June 2024. Accessed July 2024.
4 – Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139.
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.
Cameron Livingston is a General Practitioner and Partner at Dollar Health Centre General Practice in Forth Valley, Scotland, and is also a General Practitioner with special interest in sleep medicine within the Sleep Service in Greater Glasgow and Clyde, Scotland, where he has worked since 2012.
Dr Livingston graduated from Edinburgh University in 2004. Following graduation, the early part of his training took place within the National Health Service (NHS) Greater Glasgow and Clyde and NHS Forth Valley boards. He completed his General Practitioner specialty training in 2008.
Dr Livingston has gained significant expertise in the assessment and management of a wide range of sleep disorders including obstructive sleep apnoea syndrome, parasomnias, narcolepsy and insomnia.
You are being redirected to our partner’s website pro.idorsia.uk.
The content of this website contains promotional information for UK healthcare professionals and is managed by Idorsia Pharmaceuticals UK Ltd.
UK-DA-01463 | Date of preparation: April 2026
Your resource is ready to download.
Providing your details is optional, but enables us to share future updates and resources that may be of interest to you.
Download will open in a new window.
Register and stay up to date with the latest news about QUVIVIQ™▼ (daridorexant), chronic insomnia and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.
You are now leaving pro.idorsia.uk. You will now be redirected to an independent third-party site that is maintained outside of this website.
You are now leaving pro.idorsia.uk. The linked website provides helpful information if you are having trouble sleeping. It is neither owned or controlled by Idorsia Pharmaceuticals Ltd. Idorsia accepts no responsibility for the content or services of the linked site.
UK-DA-00445 | Date of preparation: Februrary 2026
Confirming your contact information and preferences means that you agree that we, Idorsia, manage your personal data in our Client Relationship Management system to document, customise, plan, and conduct our interactions with you and, to analyse and segment your interactions, interests, preferences, and scientific activities in order to interact with you in a way we think is most relevant to you.
It also means that you agree that we will send you Idorsia standard or personalised medical, company or product related information and material via email based on your choices and on what we think is of interest to you. You further consent that we process your personal data for this.
For more information about us, our processing of your personal data and your rights, please see our Privacy Notice.
You already have an account?
Register to get access to:
